This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): KX2-361, KX-02
Description: KX02 is a lipophilic dual src/pretubulin inhibitor discovered and developed by Kinex Pharmaceuticals. It is a small molecule that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including cells (T98G) that are resistant to Temodar, the most widely used chemotherapy for the treatment of malignant glioma.
Kinex and Xiangxue
In May 2012, Kinex and Xiangxue entered into a license agreement regarding KX02.
Under the terms of the agreement, Xiangxue will acquire the rights to the development and commercialization of KX02 for all oncology indications in greater China, including China, Hong Kong, Taiwan, and Singapore. Xiangxue will assume all development responsibility and associated costs in the licensed territory and will collaborate with Kinex during this process. Xiangxue will provide Kinex with an up-front payment, development milestone payments and royalties associated with product sales.
Partners: Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Additional information available to subscribers only: